WEBULL
WebtradeDownload

Summit Therapeutics (SMMT) Is Getting Fresh Attention, What Is Behind It?

Simply Wall St · 20h ago

Summit Therapeutics (SMMT) is back in focus after presenting updated Phase III HARMONi and HARMONi-2 data on ivonescimab at the IASLC World Conference on Lung Cancer, highlighting overall survival trends and safety consistency.

Recent trading suggests momentum around Summit Therapeutics is building, with a 30-day share price return of 43.60% and a 90-day gain of 29.82%, while the 1-year total shareholder return is still down 5.51%. The very large 3-year total shareholder return hints at how much sentiment has shifted over a longer horizon.

Spot 37 healthcare AI stocks that, like Summit Therapeutics, are tied to clinical and AI driven breakthroughs in complex diseases.

After a sharp move that left Summit Therapeutics trading at US$17.85 while analyst targets and intrinsic estimates sit much higher, the real tension is simple: Does fair value live closer to the recent price or the richer range of estimates ahead?

Most Popular Narrative: 39% Undervalued

On the most followed view, Summit Therapeutics screens as materially undervalued, with a fair value of about $29.21 against the last close at $17.85. That gap is anchored to one central idea: ivonescimab changing the earnings profile if the late stage pipeline lands.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

See why 4 investors see Summit Therapeutics as 39% undervalued.

Result: Fair Value of $29.21 (UNDERVALUED)

Still, the Summit Therapeutics story leans heavily on a single drug and complex late stage trials, so any regulatory setback or weaker survival data could quickly challenge this undervaluation case.

Find out about the key risks to this Summit Therapeutics narrative.

Another View: Summit Therapeutics Looks Expensive On P/B

Step away from the cash flow story and the picture changes. On P/B, Summit Therapeutics trades at about 22.6x versus roughly 2.2x for the wider US biotech group and about 8.6x for peers. That kind of gap leans toward rich expectations rather than a clear bargain. Which signal do you pay more attention to?

To pressure test this multiples picture against the underlying numbers, see what the numbers say about this price in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.

Here is how Summit Therapeutics compares on this metric against its sector and peers today

NasdaqGM:SMMT P/B Ratio as at Sep 2026
NasdaqGM:SMMT P/B Ratio as at Sep 2026

Next Steps

Conflicted by the mix of enthusiasm and caution around Summit Therapeutics? Act while the data is fresh and test the upside and downside yourself using 2 key rewards and 2 important warning signs.

Looking for more ideas beyond Summit Therapeutics?

If Summit Therapeutics has your attention, broaden your watchlist with fresh opportunities that match your risk profile, income goals, and balance sheet preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.